Group 1: Pharmaceutical and Biotechnology Industry - The pharmaceutical and biotechnology sector saw an overall increase of 0.14% last week, outperforming the CSI 300 index by 1.47 percentage points, with a current PE valuation of 29.43 times, which is at a historical mid-low level, representing a 120% premium over the CSI 300 [6][7] - Notable individual stock performances included Guangshengtang, which surged by 29.83%, followed by Haixiang Pharmaceutical at 18.64%, and Meidisi at 18.04% [6] - A significant collaboration was announced between Saint Gene and Gene Tech, involving a global R&D cooperation and licensing agreement for an RNAi therapy, with an upfront payment of $200 million and potential milestone payments totaling $1.5 billion [7][8] - The investment recommendation focuses on three main lines: biotech firms with core delivery technology and international collaboration potential, industry leaders in chronic disease areas with advanced pipelines, and key companies in the small nucleic acid supply chain benefiting from global commercialization [8] Group 2: Machinery and Equipment Industry - In January 2026, excavator sales reached 18,708 units, a year-on-year increase of 49.5%, with domestic sales up 61.4% and exports up 40.5% [11][12] - Loader sales also saw significant growth, with a total of 11,759 units sold in January, reflecting a 48.5% increase year-on-year, driven by major domestic projects [13] - The demand for excavators is expected to continue recovering due to upcoming large-scale projects in various sectors, including mining and water conservancy [12][14] - Companies like LiuGong are projected to see steady profit growth, with a forecasted net profit of 1.526 to 1.659 billion yuan for 2025, marking a 15-25% increase year-on-year [13] Group 3: Electronics Industry - The electronics sector is experiencing a recovery, with significant capital expenditure increases from major CSP manufacturers, expected to reach $670 billion in 2026, a 60% year-on-year increase [16][17] - The global semiconductor industry is projected to achieve record sales of $791.7 billion in 2025, with a 25.6% year-on-year growth, driven by demand from AI and IoT technologies [18] - Price increases are spreading from memory chips to power, analog, and MCU chips, indicating a comprehensive price surge in the semiconductor market [18] - Investment recommendations include focusing on companies benefiting from strong domestic and international demand in the AIOT sector, as well as those involved in semiconductor equipment and materials [21]

Group 1 - The company Dize Pharmaceutical announced that approximately 991,000 restricted shares will be unlocked and become tradable on February 24, 2026 [1] Group 2 - The central bank, which has been the largest buyer of gold for two consecutive years, aims to accumulate 700 tons of gold and has announced an additional purchase of 150 tons [1]

Core Viewpoint - The announcement from Dize Pharmaceutical details the second tranche of the employee stock option plan, which involves the release of 991,073 shares, representing 0.21% of the company's total share capital [1] Group 1 - The shares being released are part of the 2020 employee stock option plan, specifically the second exercise period [1] - A total of 105 shareholders are involved in this share release [1] - The shares were registered on February 16, 2023, with a lock-up period of 36 months, set to be tradable starting February 24, 2026 [1] Group 2 - The company's total share capital has changed due to previous equity incentive plans and targeted issuances, currently standing at 464,633,342 shares as of the announcement date [1]

本次股票上市流通日期为2026 年 2 月 24 日。 证券代码：688192 证券简称：迪哲医药 公告编号：2026-008 迪哲（江苏）医药股份有限公司 关于 2020 年员工股份期权计划第二个行权期第二次行 权限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上 市股数为991,073股。 本次股票上市流通总数为991,073股。 | 序 | 股份变动 | | 股份变动事项 | 股份变动数量 | 公告索引 | | --- | --- | --- | --- | --- | --- | | 号 | 时间 | | | （股） | | | 1 | 2024 | 年 2 | 2022 年度限制性 | 3,550,000 | 《2022 年度限制性股票 | | | 月 5 | 日 | 股票激励计划首 | | 激励计划首次授予部分 | | | | | 次授予部分第一 | | 第一类激励对象第一个 | | | | | 类激励对象第一 | | 归属 ...

华泰联合证券有限责任公司关于 迪哲（江苏）医药股份有限公司 2020 年员工股份期权计划 第二个行权期第二次行权限售股上市流通的核查意见 华泰联合证券有限责任公司（以下简称"保荐机构"）作为迪哲（江苏）医 药股份有限公司（以下简称"迪哲医药"或"公司"）2023 年度向特定对象发行 A 股股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易 所科创板股票上市规则》以及《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关规定履行持续督导职责，对迪哲医药 2020 年员工股 份期权计划第二个行权期第二次行权限售股上市流通事项进行了核查，核查的具 体情况如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2021 年 11 月 3 日出具的《关于同意迪哲 （江苏）医药股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕 3494 号），公司首次向社会公开发行人民币普通股（A 股）40,000,100 股，并于 2021 年 12 月 10 日在上海证券交易所科创板上市。发行完成后公司总股本为 400,000,100 股。 本次上市流通的限售股为公司首次公开 ...

文章还表示，金元顺安医疗健康、同泰大健康主题、华泰柏瑞远见智选等，成立以来跌幅也都在50%以 上。 陈铭杰2016年6月加入金元顺安基金管理有限公司，历任专户投资部投资经理等。2023年10月27日起任基金 经理，管理经验尚不足3年。 张海东曾任中原农业保险股份有限公司资产管理部总经理、中国人民健康保险股份有限公司投资管理部处 长、渤海证券北京西外大街营业部担任交易部经理兼客服务部经理、大通证券北京营业部担任柜台主管、 分析师，2025年5月加入金元顺安基金管理有限公司，从2025年8月25日担任基金经理。 2025年4季度的前十大重仓股为三生国健、百利天恒、迪哲医药、百普赛斯（301080）、百济神州、艾力 斯、药明康德（603259）、恒瑞医药（600276）、迈威生物、博瑞医药。 中国经济网北京2月6日讯 2月4日，智通财经发布《2021年成立的基金还拿不回本？五成亏损 问题究竟出在 哪？》一文。文中称，2021年大量主动权益基金密集成立，时间一晃过去四年多，A股重新站在4000点上 方，但2021年那一批在牛市尾声发车的基金却并没有集体扬眉吐气。智通财经记者以2021年成立并仍存续 的667只主动权益 ...

Core Viewpoint - Dige Medical announced the release of restricted shares from the second exercise period of its 2020 employee stock option plan, with 991,000 shares set to be listed for trading on February 24, 2026 [1] Group 1 - The number of shares being released for trading is 991,000 [1] - These shares are part of the second exercise period of the employee stock option plan initiated in 2020 [1] - The listing date for these shares is specified as February 24, 2026 [1]

金元顺安医疗健康混合C基金经理变动一览 | 起始期 | 截止期 | 基金经理 | 任职期间 | 任职回报 ② | | --- | --- | --- | --- | --- | | 2025-10-21 | ਦੇ ਹੇ | 臨絡森 张海东 | 108天 | -9.20% | | 2023-10-27 | 2025-10-20 | 臨密変 | 1年又359天 | -21.02% | | 2021-07-29 | 2023-10-26 | 贾丽杰 | 2年又89天 | -41.64% | 陈铭杰2016年6月加入金元顺安基金管理有限公司，历任专户投资部投资经理等。2023年10月27日起任 基金经理，管理经验尚不足3年。 张海东曾任中原农业保险股份有限公司资产管理部总经理、中国人民健康保险股份有限公司投资管理 部处长、渤海证券北京西外大街营业部担任交易部经理兼客服务部经理、大通证券北京营业部担任柜台主 管、分析师，2025年5月加入金元顺安基金管理有限公司，从2025年8月25日担任基金经理。 中国经济网北京2月6日讯 2月4日，智通财经发布《2021年成立的基金还拿不回本？五成亏损 问题究竟 出在哪？》一文。文 ...

系统性升级。 《投资者网》蔡俊 1月，港股再掀创新药IPO盛宴。 相较2018年至2021年的热潮，本次盛宴在底层逻辑上有了深刻改变。一方面，资本更趋理性，不再以故事驱动估值判定，而是从确定性的结果中给出价值。 另一方面，本轮参与企业的成分更为多元，既有Biotech大军，也有两地上市及分拆上市的新形态。 说到底，新一轮的盛宴以更升级的方式完成自我进化。这轮在创新药行情后紧接而来的IPO热潮能持续多久，值得观察。 盛宴再度开启 截至1月，共有7家创新药企向港交所递交招股书，包括博锐生物、先声再明、赜灵生物、亦诺微、勤浩医药、普祺医药、迪哲医药等。 期间，精锋医疗和瑞博生物成功在港交所挂牌，分别对应手术机器人、小核酸药物等赛道，合计募资超40亿元。 之所以选择港股，在于大多数企业仍亏损，由此适配港交所的18A/18C规则，即未盈利科技企业至少1个核心产品进入临床阶段，就可走快速通道冲击IPO。 而且，这些企业的募资需求相当明确，用途也高度一致：核心用于管线临床推进、商业化产能建设、技术平台升级等。其中，迪哲医药已上市科创板，因此 本次意在冲击"A+H"两地上市。 截至目前，迪哲医药的A股市值超250亿元。202 ...

Core Viewpoint - Dize Pharmaceutical has submitted an application for a Hong Kong stock listing, aiming to leverage the international financing platform and higher valuation standards of the Hong Kong market to enhance its global market presence and attract international investors [1][2]. Group 1: Company Developments - Dize Pharmaceutical has achieved a revenue of 586 million yuan in the first three quarters, representing a 73% year-on-year increase, and is expected to reach approximately 800 million yuan for the full year, with a projected growth of 122.28% [2]. - The company has achieved commercial profitability, with product revenues covering all operating expenses beyond R&D costs, marking a significant milestone [2]. - The launch of its core product, Shuwozhe®, which received FDA accelerated approval, has established Dize's capability to transition from laboratory to international market, opening new overseas growth opportunities [2]. Group 2: Market Strategy - The decision to list in Hong Kong aligns with Dize's strategy to utilize the advantages of dual listings to attract international investors and facilitate collaboration with multinational pharmaceutical companies [1]. - Dize's product pipeline is developed with a global synchronization strategy, aiming to create a differentiated matrix of globally innovative and best-in-class potential products [1]. - The company plans to maintain a high level of R&D investment, with ongoing progress in product development and expansion of indications for already launched products [2].